Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
United States Janet Graesser Jennifer Zibuda Groupa Strep Exchange Commission Company Potential Pneumococcal Conjugate Vaccine
Source: globenewswire.com